While in progressing PCA, PSMA expression increases with Gleason score and is associated with recurring serum PSA levels; progression into neuroendocrine prostate cancer (NEPC) is accompanied by decreased PSMA and increased levels of neuroendocrine genes such as FOXA1, ENO2 and SYP [68]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.